Read the full narrative on Hims & Hers Health (it's free!) Hims & Hers Health's narrative projects $3.6 billion revenue and $248.5 million earnings by 2029
At Birmingham Health, we use GLP-1based medications as part of a personalized, root-cause approach to weight and metabolic health
Compounded semaglutide is not FDA-approved, has not undergone FDA review for safety or effectiveness, and is not the same as, nor equivalent to, Ozempic or Wegovy
Paul Hetrick, PharmD Published: Mar 27, 2025 Key takeaway: If Wegovy is too expensive, unavailable, or not the right fit, several strong alternatives exist including tirzepatide (Zepbound), oral semaglutide, and non-GLP-1 medications
J Diabetes Res (2015) 2015:19